Development of a hypoxia-responsive vector for tumor-specific gene therapy

Gene Therapy

Volumn 7, Issue 6, 2000, Pages 493-498

  Shibata, T ^a   Giaccia, A J ^a   Brown, J M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Hypoxia inducible factor 1; Hypoxia responsive element; Tumor hypoxia; Vascular endothelial growth factor

Indexed keywords

LUCIFERASE; MESSENGER RNA; VASCULOTROPIN;

ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE INDUCTION; GENE THERAPY; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROMOTER REGION; RNA DEGRADATION; TRANSCRIPTION REGULATION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0034017489     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301124     Document Type: Article

References (38)

1. Martiniello WR et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 1998; 9: 1617-1626.
2. Lan KH et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res 1997; 57: 4279-4284.
3. Harris JD et al. Gene therapy for cancer using tumour-specific prodrug activation. Gene Therapy 1994; 1: 170-175.
4. Fox ME et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia (published erratum appears in Gene Therapy 1996; 3: 741). Gene Therapy 1996; 3: 173-178.
5. Lemmon MJ et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Therapy 1997; 4: 791-796.
6. Dachs GU et al. Targeting gene expression to hypoxic tumor cells. Nature Med 1997; 3: 515-520.
7. Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998; 42: 913-916.
8. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
9. Brizel DM et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
10. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45-50.
11. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-39.
12. Goldberg MA et al. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987; 84: 7972-7976.
13. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
14. Shweiki D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
15. Semenza GL et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88: 5680-5684.
16. Madan A, Curtin PT. A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc Natl Acad Sci USA 1993; 90: 3928-3932.
17. Semenza GL et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269: 23757-23763.
18. Semenza GL et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-32537.
19. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269: 4355-4359.
20. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995; 370: 203-208.
21. Forsythe JA et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
22. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271: 2746-2753.
23. Caput D et al. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986; 83: 1670-1674.
24. Wilson T, Treisman R. Removal of poly(A) and consequent degradation of c-fos mRNA facilitated by 3′ AU-rich sequences. Nature 1988; 336: 396-399.
25. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-667.
26. Levy NS, Goldberg MA, Levy AP. Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim Biophys Acta 1997; 1352: 167-173.
27. Damert A et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997; 57: 3860-3864.
28. 2 tension. Am J Physiol 1996; 27: C1172-C1180.
29. Dachs GU, Stratford IJ. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer 1996; 74: S126-S132.
30. Adam MF et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999; 21: 146-153.
31. Claffey KP et al. Identification of a human VPF/VEGF 3′ untranslated region mediating hypoxia-induced mRNA stability. Mol Biol Cell 1998; 9: 469-481.
32. Shyu AB, Greenberg ME, Belasco JG. The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev 1989; 3: 60-72.
33. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
34. Gossen M et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
35. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67: 1163-1170.
36. Mazure NM et al. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56: 3436-3440.
37. Liu Y et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995; 77: 638-643.
38. Boshart M et al. A very strong enhancer is located upstream of an immediate-early gene of human cytomegalovirus. Cell 1985; 41: 521-530.